ESMO 2017 Immuno-Oncology
Dr. Suresh Ramalingam presents the results of the FLAURA study
Dr. Suresh Ramalingam presents the results of the FLAURA study (presidental symposium): Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC.
